AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20430356 — intervention group
Group type: COMPARATOR
Intervention: Usual teaching
Number of subjects: 43
Study 18281658 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib 150 mg orally daily until progression
Number of subjects: 103
Study 18281658 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin (AUC 6) and paclitaxel (200 mg/m² day 1 every 3 weeks) for up to four cycles
Number of subjects: 103
Study 15969834 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional vigilance task
Number of subjects: 0
Study 15969834 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified vigilance task
Number of subjects: 0
Study 14550317 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal Food Intake (NFI)
Number of subjects: 16
Study 14550317 — intervention group
Group type: EXPERIMENTAL
Intervention: Food Restriction (RFI)
Number of subjects: 16
Study 14550317 — intervention group
Group type: COMPARATOR
Intervention: Control slides
Number of subjects: 16
Study 10942632 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment (9.5 microg/kg/day) for 9 months
Number of subjects: 30
Study 10942632 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 8630191 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive outpatient therapy (1 hr each of physical and occupational therapy, four times per week, for 12 weeks)
Number of subjects: 49
Study 8630191 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment supplied)
Number of subjects: 49
Study 8630191 — intervention group
Group type: EXPERIMENTAL
Intervention: Treated patients
Number of subjects: 49
Study 8400928 — intervention group
Group type: EXPERIMENTAL
Intervention: levodopa/dopa decarboxylase inhibitor alone (arm 1)
Number of subjects: 782
Study 8400928 — intervention group
Group type: EXPERIMENTAL
Intervention: levodopa/decarboxylase inhibitor/selegiline in combination (arm 2)
Number of subjects: 782
Study 8400928 — intervention group
Group type: EXPERIMENTAL
Intervention: bromocriptine (arm 3)
Number of subjects: 782
Study 3553802 — intervention group
Group type: EXPERIMENTAL
Intervention: Killed, armadillo-derived M. leprae vaccine (1.5 x 10^7 bacilli)
Number of subjects: 4
Study 3553802 — intervention group
Group type: EXPERIMENTAL
Intervention: Killed, armadillo-derived M. leprae vaccine (5 x 10^7 bacilli)
Number of subjects: 4
Study 3553802 — intervention group
Group type: EXPERIMENTAL
Intervention: Killed, armadillo-derived M. leprae vaccine (1.5 x 10^8 bacilli)
Number of subjects: 4
Study 3553802 — intervention group
Group type: EXPERIMENTAL
Intervention: Killed, armadillo-derived M. leprae vaccine (5 x 10^8 bacilli)
Number of subjects: 4
Study 29306882 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal Imaging (TI)
Number of subjects: 47
Study 29306882 — intervention group
Group type: COMPARATOR
Intervention: Chest X-ray (CXR)
Number of subjects: 47
Study 27536869 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary protein at 10%
Number of subjects: 22
Study 27536869 — intervention group
Group type: COMPARATOR
Intervention: Dietary protein at 15%
Number of subjects: 22
Study 27536869 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary protein at 25%
Number of subjects: 22
Study 23200175 — intervention group
Group type: EXPERIMENTAL
Intervention: Selumetinib plus docetaxel
Number of subjects: 87
Study 23200175 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus docetaxel
Number of subjects: 87
Study 21391924 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) - 100 mg/kg bolus IV over 15 min, followed by 40 mg/kg/day IV infusion for 24 h
Number of subjects: 48
Study 21391924 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 48
Study 21391924 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 48
Study 19364873 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine (SP) single-dose treatment
Number of subjects: 89
Study 17572835 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity back-strengthening exercise
Number of subjects: 80
Study 17572835 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 80
Study 15084901 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefazodone (200-600 mg/day)
Number of subjects: 41
Study 15084901 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 11532112 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous hemodiafiltration
Number of subjects: 166
Study 11532112 — intervention group
Group type: COMPARATOR
Intervention: Intermittent hemodialysis (IHD)
Number of subjects: 166
Study 11532112 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 166
Study 9771299 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 ml kg‐1 of crystalloid fluid preload over 20 min
Number of subjects: 58
Study 9771299 — intervention group
Group type: COMPARATOR
Intervention: No fluids before induction of anaesthesia
Number of subjects: 58
Study 7830390 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate maltodextrin supplement (MD; 5% maltodextrin + 2% fructose) at dosage of 0.25 g.kg‐1 body weight (mean intake rate, total: 37 g.h‐1, 148 g)
Number of subjects: 14
Study 7830390 — intervention group
Group type: COMPARATOR
Intervention: Non-caloric placebo (PL)
Number of subjects: 14
Study 7830390 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate maltodextrin supplement (MD)
Number of subjects: 14
Study 3071596 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 50 mg once daily
Number of subjects: 30
Study 3071596 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 100 mg once daily
Number of subjects: 30
Study 3071596 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 30827971 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally sensitive, church-based health-promotion intervention over six weeks.
Number of subjects: 321
Study 30827971 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group (no intervention).
Number of subjects: 321
Study 27933698 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir 400 mg and weight-based ribavirin (1000 or 1200 mg) daily for 16 weeks
Number of subjects: 117
Study 27933698 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir 400 mg and weight-based ribavirin (1000 or 1200 mg) daily for 24 weeks
Number of subjects: 117
Study 27933698 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir plus ribavirin therapy
Number of subjects: 117
Study 25938158 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dexmedetomidine at a dose of 0.2 μg/kg.h for 12 hours
Number of subjects: 156
Study 25938158 — intervention group
Group type: COMPARATOR
Intervention: Intravenous normal saline for 12 hours
Number of subjects: 156
Study 23362991 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific psychological intervention (6 sessions) along with fluoxetine
Number of subjects: 15
Study 23362991 — intervention group
Group type: COMPARATOR
Intervention: Non-specific psychological intervention (6 sessions) along with fluoxetine
Number of subjects: 15
Study 21979458 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic sacrocolpopexy
Number of subjects: 78
Study 21979458 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic sacrocolpopexy
Number of subjects: 78
Study 18778179 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (10 mg/day) for 16 weeks
Number of subjects: 66
Study 21809720 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lignocaine with 1:80 000 adrenaline
Number of subjects: 33
Study 21809720 — intervention group
Group type: COMPARATOR
Intervention: 2% lignocaine without vasoconstrictor (plain lignocaine)
Number of subjects: 33
Study 16138713 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release fluvastatin 80 mg/day
Number of subjects: 61
Study 16138713 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release fluvastatin 40 mg/day
Number of subjects: 61
Study 11876598 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical corticosteroid (budesonide aqueous nasal spray: 128 microg b.i.d.)
Number of subjects: 100
Study 11876598 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 11876598 — intervention group
Group type: COMPARATOR
Intervention: Other scoring system
Number of subjects: 100
Study 10322793 — intervention group
Group type: EXPERIMENTAL
Intervention: Differential DNA fragments isolated from cancerous tissues using arbitrary primer polymerase chain reaction (AP‐PCR).
Number of subjects: 12
Study 10322793 — intervention group
Group type: COMPARATOR
Intervention: Southern blot analysis of genomic DNA from cancerous and non-cancerous tissues.
Number of subjects: 12
Study 7649341 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg dropropizine orally, three times daily for 3 days
Number of subjects: 258
Study 7649341 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/kg levodropropizine orally, three times daily for 3 days
Number of subjects: 258
Study 2668428 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone 2 g once a day
Number of subjects: 171
Study 2668428 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime 2 g every 4 h
Number of subjects: 171
Study 322677 — intervention group
Group type: EXPERIMENTAL
Intervention: Reproterol (Bronchospasmin)
Number of subjects: 16
Study 322677 — intervention group
Group type: EXPERIMENTAL
Intervention: Orciprenaline
Number of subjects: 16
Study 322677 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 29724729 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 115
Study 29724729 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine
Number of subjects: 115
Study 27886078 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 µg vitamin B12 and 400 µg folic acid daily
Number of subjects: 2919
Study 27886078 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2919
Study 24679384 — intervention group
Group type: EXPERIMENTAL
Intervention: Suicide Cognitions Scale (SCS)
Number of subjects: 326
Study 22314083 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vitamin D supplement (1000 IU cholecalciferol/day)
Number of subjects: 477
Study 22314083 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 477
Study 20538094 — intervention group
Group type: EXPERIMENTAL
Intervention: RIX4414
Number of subjects: 100
Study 18785056 — intervention group
Group type: EXPERIMENTAL
Intervention: Providing information about mnemonic features before the test
Number of subjects: 0
Study 18785056 — intervention group
Group type: EXPERIMENTAL
Intervention: Calling attention to features in test instructions
Number of subjects: 0
Study 18785056 — intervention group
Group type: COMPARATOR
Intervention: Asking participants to rate their phenomenal experience
Number of subjects: 0
Study 15867125 — intervention group
Group type: COMPARATOR
Intervention: 1 throat swab
Number of subjects: 363
Study 15867125 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 throat swabs
Number of subjects: 363
Study 12803583 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MP, 15 mg kg‐1, n = 12)
Number of subjects: 36
Study 12803583 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirilazad mesylate (TM, 10 mg kg‐1, n = 12)
Number of subjects: 36
Study 12803583 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL, NaCl, n = 12)
Number of subjects: 36
Study 10372428 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (3 mg.kg‐1)
Number of subjects: 10
Study 10372428 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 8706483 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl-L-cysteine
Number of subjects: 20
Study 8706483 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 1752851 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine 25‐50 mg (N = 9)
Number of subjects: 21
Study 1752851 — intervention group
Group type: COMPARATOR
Intervention: Placebo (N = 12)
Number of subjects: 21
Study 1752851 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular route of administration
Number of subjects: 21
Study 1752851 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral route of administration
Number of subjects: 21
Study 6789793 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate plus imipramine hydrochloride
Number of subjects: 75
Study 6789793 — intervention group
Group type: COMPARATOR
Intervention: Lithium carbonate plus placebo
Number of subjects: 75
Study 6789793 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 75
Study 31175812 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant weight and length SITAR parameters
Number of subjects: 902
Study 30027612 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily application of the antiaging cream (0.1% RAL, GGO, Pre-tocopheryl) for 8 weeks
Number of subjects: 55
Study 30027612 — intervention group
Group type: COMPARATOR
Intervention: Three sequential glycolic acid (GA) peels (20%, 50%, and 70%) every 2-3 weeks
Number of subjects: 55
Study 26936453 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Pain Coding System (CPCS)
Number of subjects: 45
Study 24335546 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial spin-labeling-MRI
Number of subjects: 13
Study 24335546 — intervention group
Group type: COMPARATOR
Intervention: H2[15O]-PET
Number of subjects: 13
Study 22471260 — intervention group
Group type: EXPERIMENTAL
Intervention: PLDLA implant arthroplasty
Number of subjects: 29
Study 22471260 — intervention group
Group type: COMPARATOR
Intervention: Tendon interposition
Number of subjects: 29
Study 20595906 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir 200 mg
Number of subjects: 0
Study 20595906 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17482177 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdose GnRH agonist flare (ML)
Number of subjects: 534
Study 17482177 — intervention group
Group type: COMPARATOR
Intervention: GnRH antagonist/letrozole (AL)
Number of subjects: 534
Study 16126047 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG (probiotics)
Number of subjects: 96
Study 16126047 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 11840407 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparinized saline
Number of subjects: 49
Study 11840407 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 49
Study 12147332 — intervention group
Group type: EXPERIMENTAL
Intervention: Vanillin (pleasant odor)
Number of subjects: 0
Study 12147332 — intervention group
Group type: EXPERIMENTAL
Intervention: Indole (unpleasant odor)
Number of subjects: 0
Study 12147332 — intervention group
Group type: EXPERIMENTAL
Intervention: Right nostril stimulation
Number of subjects: 0
Study 12147332 — intervention group
Group type: EXPERIMENTAL
Intervention: Left nostril stimulation
Number of subjects: 0
Study 12147332 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity judgment task
Number of subjects: 0
Study 12147332 — intervention group
Group type: EXPERIMENTAL
Intervention: Affective judgment task
Number of subjects: 0
Study 9524897 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcholine (ACH) infusion
Number of subjects: 10
Study 8121734 — intervention group
Group type: COMPARATOR
Intervention: Maternal cigarette smoking (10 or more cigarettes per day during pregnancy)
Number of subjects: 400
Study 8121734 — intervention group
Group type: EXPERIMENTAL
Intervention: No maternal cigarette smoking during pregnancy
Number of subjects: 400
Study 2477909 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine (120 mg)
Number of subjects: 10
Study 2477909 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 359252 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflunisal
Number of subjects: 50
Study 359252 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 50
Study 359252 — intervention group
Group type: COMPARATOR
Intervention: Naproxen
Number of subjects: 50
Study 30481999 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemadsorption during CPB (Cytosorb®)
Number of subjects: 40
Study 30481999 — intervention group
Group type: COMPARATOR
Intervention: Control group (no hemadsorption)
Number of subjects: 40
Study 28029445 — intervention group
Group type: EXPERIMENTAL
Intervention: E10030 1.5 mg in combination with ranibizumab 0.5 mg
Number of subjects: 449
Study 28029445 — intervention group
Group type: EXPERIMENTAL
Intervention: E10030 0.3 mg in combination with ranibizumab 0.5 mg
Number of subjects: 449
Study 28029445 — intervention group
Group type: COMPARATOR
Intervention: Sham in combination with ranibizumab 0.5 mg (anti-VEGF monotherapy)
Number of subjects: 449
Study 26856015 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental ultra‐low abrasivity desensitizing dentifrice (RDA ‐12)
Number of subjects: 142
Study 26856015 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental low abrasivity desensitizing dentifrice (RDA ‐40)
Number of subjects: 142
Study 26856015 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard fluoride dentifrice (RDA ‐80)
Number of subjects: 142
Study 26856015 — intervention group
Group type: EXPERIMENTAL
Intervention: Whitening dentifrice (RDA ‐142)
Number of subjects: 142
Study 23896222 — intervention group
Group type: EXPERIMENTAL
Intervention: Don't Panic Online, an Internet‐based self‐help course for mild panic symptoms, based on cognitive behavioral principles and includes guidance by email.
Number of subjects: 126
Study 23896222 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 126
Study 21843430 — intervention group
Group type: EXPERIMENTAL
Intervention: Free water intake (treatment group)
Number of subjects: 54
Study 21843430 — intervention group
Group type: COMPARATOR
Intervention: Control group (no water intake)
Number of subjects: 54
Study 19841765 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber-reinforced composites (FRC) - Angelus Fibrex Ribbon, DentaPreg Splint, ever-Stick Ortho, Ribbond
Number of subjects: 80
Study 19841765 — intervention group
Group type: COMPARATOR
Intervention: Stainless steel wire - Quad Cat Wire (various application methods)
Number of subjects: 80
Study 16636167 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-chamber pacing (DDDR)
Number of subjects: 2010
Study 16636167 — intervention group
Group type: COMPARATOR
Intervention: Ventricular pacing (VVIR)
Number of subjects: 2010
Study 16636167 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative percent ventricular pacing (Cum%VP) >80
Number of subjects: 2010
Study 16636167 — intervention group
Group type: COMPARATOR
Intervention: Cumulative percent ventricular pacing (Cum%VP) ≤80
Number of subjects: 2010
Study 16636167 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative percent ventricular pacing (Cum%VP) >40 or ≤80
Number of subjects: 2010
Study 16636167 — intervention group
Group type: EXPERIMENTAL
Intervention: QRS duration (QRSd)
Number of subjects: 2010
Study 16636167 — intervention group
Group type: EXPERIMENTAL
Intervention: Low baseline ejection fraction (EF)
Number of subjects: 2010
Study 16636167 — intervention group
Group type: EXPERIMENTAL
Intervention: Drugs for atrial fibrillation
Number of subjects: 2010
Study 15658648 — intervention group
Group type: EXPERIMENTAL
Intervention: Shexiang Baoxin pill (SBP)
Number of subjects: 111
Study 11506052 — intervention group
Group type: EXPERIMENTAL
Intervention: systematic desensitization
Number of subjects: 40
Study 11506052 — intervention group
Group type: EXPERIMENTAL
Intervention: humor desensitization
Number of subjects: 40
Study 11506052 — intervention group
Group type: COMPARATOR
Intervention: untreated controls
Number of subjects: 40
Study 9032192 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide (800 mg twice daily for 2 weeks)
Number of subjects: 23
Study 9032192 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone (30 mg daily for 2 weeks)
Number of subjects: 23
Study 8498631 — intervention group
Group type: EXPERIMENTAL
Intervention: Random repeat recall method (14 random days during three 30-day waves)
Number of subjects: 142
Study 8498631 — intervention group
Group type: EXPERIMENTAL
Intervention: Random repeat recall method (2 random days during each wave)
Number of subjects: 142
Study 8498631 — intervention group
Group type: COMPARATOR
Intervention: Summary measure from follow-up telephone interviews
Number of subjects: 142
Study 2891867 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical indometacin
Number of subjects: 60
Study 2891867 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker and pilocarpine 2%
Number of subjects: 60
Study 2891867 — intervention group
Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 60
Study 31568378 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-oriented functional training
Number of subjects: 52
Study 31568378 — intervention group
Group type: EXPERIMENTAL
Intervention: Wii Fit intervention
Number of subjects: 52
Study 29320647 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide
Number of subjects: 863
Study 29320647 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 863
Study 26758700 — intervention group
Group type: EXPERIMENTAL
Intervention: α‐MSH levels in obese children (1194±865 ng/mL)
Number of subjects: 175
Study 26758700 — intervention group
Group type: EXPERIMENTAL
Intervention: AgRP levels in obese children (828±417 ng/mL)
Number of subjects: 175
Study 26758700 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between plasma α‐MSH and AgRP levels
Number of subjects: 175
Study 24313633 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline 100 mg daily for 4 weeks (after initial 8 weeks of 50 mg)
Number of subjects: 218
Study 24313633 — intervention group
Group type: COMPARATOR
Intervention: Sertraline 50 mg daily for 8 weeks, continued for 4 weeks
Number of subjects: 218
Study 24313633 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline 50 mg daily for 8 weeks
Number of subjects: 218
Study 24313633 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline 100 mg daily for 4 weeks
Number of subjects: 218
Study 22968625 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral supplementation (Se and Zn) for 60 days
Number of subjects: 144
Study 22968625 — intervention group
Group type: COMPARATOR
Intervention: Healthy male subjects (control group)
Number of subjects: 144